Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
Masimo Corporation MASI reported second-quarter 2020 adjusted earnings per share (EPS) of 85 cents, which surpassed the Zacks Consensus Estimate of 78 cents by 8.9%. Earnings improved 11.8% from the year-ago quarter.
Total revenues (including Royalty) improved 31.1% year over year to $301 million and beat the Zacks Consensus Estimate of $289.33 million by 4%.
Product revenues in the second quarter totaled $301 million, up 31.1% from the year-ago quarter and 32% at constant currency (cc).
Per management, shipments of non-invasive technology boards and monitors surged 174% to a record 165600 in the quarter.
In the quarter under review, gross profit totaled $191.6 million, up 24.1% year over year. Gross margin was 63.6%, down 355 basis points (bps).
Adjusted operating profit in the quarter totaled $62.2 million, up 19.7% from a year ago. Adjusted operating margin contracted 196 bps to 20.7% in the quarter.
Masimo Corporation Price, Consensus and EPS Surprise
Given the uncertainties surrounding the COVID-19 pandemic and its impact on the company’s normal business patterns, Masimo has not issued any guidance for 2020.
Masimo exited the second quarter on a strong note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter under review. The company’s non-invasive technology shipments also surged in the quarter. In fact, management foresees increased shipments for the quarters ahead.The recent launch of the Masimo SafetyNet, designed to help fight the coronavirus pandemic, buoys optimism. The outbreak has boosted demand for the company’s products among direct and OEM customers.
On the flip side, contraction of both margins is a concern. Masimo’s Royalty and Other segment saw no contribution during the quarter. Further, the company faces fierce competition from MedTech bigwigs.
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are ViewRay, Inc. VRAY, OPKO Health OPK and ResMed Inc. RMD. Each carries a Zacks Rank #2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank (Strong buy) stocks here.
The Zacks Consensus Estimate for ViewRay’s second-quarter 2020 bottom line is pegged at a loss of 16 cents per share, indicating 50% narrower loss than the year-ago reported quarter figure.
The Zacks Consensus Estimate for OPKO Health’s second-quarter 2020 bottom line stands at a loss of 7 cents per share, suggesting a 30% improvement from the year-ago period. The same for revenues is pegged at $234.6 million, calling for a 3.6% increase from the year-earlier reported figure.
The Zacks Consensus Estimate for ResMed’s fourth-quarter fiscal 2020 revenues is at $710.9 million, calling for a 0.9% increase from the year-earlier reported figure. The same for adjusted earnings per share stands at 99 cents, indicating a 4.2% rise from the year-ago reported figure.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained an impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Click to get this free report
Masimo Corporation (MASI): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
ViewRay, Inc. (VRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research